Biogen opts in for Ionis' ALS candidate, plans pivotal trial

Biogen opts in for Ionis' ALS candidate, plans pivotal trial

Submitted by admin on December 6, 2018 - 6:56pm
Source: 
BioCentury
News Tags: 
BIIB067
Biogen
Ionis Pharmaceuticals
ALS
Headline: 
Biogen opts in for Ionis' ALS candidate, plans pivotal trial
snippet: 

Biogen Inc. (NASDAQ:BIIB) exercised its option for exclusive, worldwide rights to BIIB067 (IONIS-SOD1Rx) from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) to treat amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) mutations.

Do Not Allow Advertisers to Use My Personal information